- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Leads the Way in M&A
The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal.
The pharma, medical and biotech industry is the leading sector for M&A activity this year, Mergermarket‘s Q2 M&A stats reveal. The sector’s deals have been valued at US$252.5 bn, a 16.9% market share in global M&A. Deal value is 48.2% above the whole of 2013’s value, and four deals account for a 61.3% share in the sector’s total activity.
Pharma, medical and biotech companies were the most targeted during the first six months of 2014, says Mergermarket; the value already exceeds the annual values of every other year since 2006.
Deals valued at US$ 84.8 bn currently have a 19.9% share in total European M&A, a considerable increase from a 5.4% share this time last year. US bidders accounted for a 71.8% share of European pharma, medical and biotech M&A activity, with deals being announced for tax benefits such as the US$ 45.9bn acquisition of Ireland’s Covidien by Medtronic.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
